🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalUK Boots vs LloydsPharmacy — 12 month update Page 5

UK Boots vs LloydsPharmacy — 12 month update

LipidDoc_ATL Mon, Dec 15, 2025 at 8:53 PM 39 replies 1,780 viewsPage 5 of 8
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
Jan 4, 2026 at 12:09 PM#21
MarkLI_maint said:
Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.

This matches mine closely enough to be worth saying so out loud. Nothing to add that would improve it.

21 19paul_denver, TinaHashiRN, robert_kc and 18 others
Reply Quote Save Share Report
cory_ATX
Member
456
2,123
Jul 2024
Austin, TX
Jan 11, 2026 at 9:25 PM#22
MarkLI_maint said:
Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.

Coming at MarkLI_maint’s question from a different direction. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

22 20andrew_nyc, Dr.EndoEP, GraceAZ_72 and 19 others
Reply Quote Save Share Report
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Jan 19, 2026 at 6:46 AM#23

Adding the numbers, since they settle part of this. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

23 21AttorneyGrant, DebRD_ATL, KristenIndy and 20 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
hyun_seoul
Member
345
1,456
Jul 2024
Seoul, KR
Jan 26, 2026 at 4:11 PM#24

One thing that is still open after MarkLI_maint’s answer:

How would you tell the difference between that and the alternative explanation?

24 22BariatricNurseD, MASHdoc_SA, GenomicsKate and 21 others
Reply Quote Save Share Report
CanadaChris
Member
234
890
Nov 2024
Toronto, CA
Feb 3, 2026 at 1:41 AM#25
Dr.PulmRoch said:
Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

I am going to disagree with the direction of travel here. The thread has converged on the tidiest answer rather than the best-supported one, and those are not the same thing.

25 23lori_vegas, Dr.PulmRoch, maya_sedona and 22 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register